Each case of CLABSI adds roughly $46,000 in direct US medical costs. The global economic burden runs into billions, yet proven prevention strategies can cut infection rates by more than half.
Key Takeaways
- US annual CLABSI direct cost $46,000 per case 2023 dollars, CDC/Zimlichman study update
- In the United States, the pooled CLABSI incidence rate in adult ICUs was 1.0 infections per 1,000 central line-days from 2015-2019 according to CDC's National Healthcare Safety Network (NHSN) data
- CLABSI mortality rate 15-25% in adults, CDC estimate attributable
- Chlorhexidine bath reduces CLABSI by 45% (RR 0.55, 95% CI 0.42-0.72), meta-analysis 12 RCTs
- Femoral vein catheterization increases CLABSI risk by 2.5-fold compared to subclavian, CDC guidelines meta-analysis
CLABSI rates stayed low, highlighting the impact of consistent infection prevention efforts.
Related reading
01 · Category
Economics21 stats
01
US annual CLABSI direct cost $46,000per case 2023 dollars, CDC/Zimlichman study update
02
Attributable cost of CLABSI $20,815per ICU case (2019), matched analysis 1,000 cases
03
Annual US CLABSI economic burden $670 million in direct costs, HAI report 2022
04
Neonatal CLABSI cost $36,000per episode vs $7,500 without, Vermont Oxford
05
CLABSI LOS extension costs $16,000per case in Medicare, CMS data
06
Prevention bundle ROI: $7saved per $1 invested in CLABSI reduction, Michigan study
07
PICC-CLABSI cost $15,549vs $12,178 CVC in outpatients
08
MDR-CLABSI additional cost $28,000per case US, IDSA
09
UK NHS CLABSI cost £10,000 per case 2021
10
Cancer center CLABSI $52,000per episode, insurance claims
11
Global CLABSI annual cost $3.9 billion low/middle income, WHO
12
Dialysis CLABSI cost $19,500per infection KDOQI
13
Bundle implementation saves $1,800-$12,400 per CLABSI prevented, meta-cost
14
Pediatric CLABSI $27,000attributable cost, NIS database
15
Australian CLABSI cost AUD$40,000per case 2020
16
Excess mortality cost $100,000+ per CLABSI death, VSL estimate
17
LTACH CLABSI $55,000per case CMS
18
CHG bath program cost-effective at $2,500per CLABSI averted
19
Antimicrobial catheter savings $4,200per prevented infection, UK HTA
20
Brazilian CLABSI cost BRL 50,000 per ICU case
21
Lost productivity post-CLABSI $15,000per survivor, economic model
Interpretation
Economics Interpretation
While the human cost of a CLABSI is immeasurable, the financial hemorrhage it inflicts—averaging tens of thousands per case and bleeding billions from healthcare systems globally—makes prevention not just an ethical imperative but a stunningly obvious fiscal one.
02 · Category
Epidemiology30 stats
01
In the United States, the pooled CLABSI incidence rate in adult ICUs was 1.0 infections per 1,000 central line-days from 2015-2019 according to CDC's National Healthcare Safety Network (NHSN) data
02
Globally, CLABSI incidence in neonatal ICUs averages 5.5 per 1,000 central line-days, higher in low-resource settings at 15.5 per 1,000, per WHO 2022 report
03
In European ICUs, standardized infection ratio (SIR) for CLABSI decreased from 1.2 in 2010 to 0.7 in 2020, ECDC data shows
04
US pediatric ICUs reported CLABSI rate of 0.8 per 1,000 central line-days in 2021 NHSN
05
In cancer patients with central lines, CLABSI incidence is 4.2 per 1,000 catheter-days, meta-analysis of 20 studies
06
Australian ICUs CLABSI rate fell to 0.5 per 1,000 line-days post-2017 bundle implementation, ANZICS data
07
In long-term acute care hospitals (LTACHs), CLABSI SIR was 1.1 in 2022 per CMS data
08
Brazilian neonatal units report CLABSI at 8.2 per 1,000 central line-days, multicenter study 2018-2020
09
UK NHS ICUs CLABSI rate 0.9 per 1,000 line-days in 2021, ICNARC audit
10
In US hospitals, CLABSI attributable to short-term catheters is 70% of cases, NHSN 2023
11
Indian ICUs show CLABSI incidence of 12.4 per 1,000 line-days, INICC network 2019
12
Canadian surveillance data: CLABSI in adult ICUs 1.2 per 1,000 line-days 2020
13
South Korean hospitals CLABSI rate 2.1 per 1,000 catheter-days in hematology units, 2021 study
14
In US Veterans Affairs hospitals, CLABSI SIR 0.6 in 2022
15
Mexican ICUs CLABSI incidence 7.6 per 1,000 line-days, INICC 2020
16
French national data: CLABSI in ICUs 1.4 per 1,000 line-days 2019
17
Turkish neonatal ICUs CLABSI 9.8 per 1,000 line-days, multicenter 2021
18
Italian ICUs post-COVID CLABSI rose to 2.3 per 1,000 line-days 2021
19
Spanish hospitals CLABSI SIR 0.8 in 2022 ENVIN registry
20
US burn ICUs CLABSI 3.2 per 1,000 line-days NHSN 2021
21
Saudi Arabian ICUs CLABSI 4.5 per 1,000 line-days, 2020 study
22
German ICUs CLABSI rate 0.75 per 1,000 line-days 2020
23
Argentine neonatal CLABSI 10.1 per 1,000 line-days INICC
24
Dutch ICUs CLABSI SIR 0.4 in 2022 national PREZIES
25
Chinese ICUs CLABSI 3.8 per 1,000 line-days 2021 meta-analysis
26
Israeli hospitals CLABSI in oncology 5.1 per 1,000 days, 2019
27
Egyptian ICUs CLABSI 11.2 per 1,000 line-days, 2022
28
Swedish ICUs CLABSI 0.6 per 1,000 line-days 2021 STRAMA
29
Colombian neonatal CLABSI 13.4 per 1,000 line-days INICC 2020
30
US hematology wards CLABSI 2.9 per 1,000 line-days 2022
Interpretation
Epidemiology Interpretation
The world's fight against bloodstream infections reveals a harsh geographic lottery: a baby in a modern ICU has better odds than a soldier, while a newborn in a low-resource setting faces a battlefield where the enemy multiplies by fifteen.
03 · Category
Outcomes23 stats
01
CLABSI mortality rate 15-25% in adults, CDC estimate attributable
02
Crude mortality 36% in CLABSI ICU patients vs 22% without, matched cohort
03
Attributable mortality 18.4% (95% CI 9.7-28.4%) for CLABSI, meta-analysis 60 studies
04
Pediatric CLABSI mortality 7-12%, NHSN 2021 data
05
Sepsis from CLABSI lengthens ICU stay by 7.5 days median
06
30-day mortality 25% in cancer CLABSI, prospective study 500 cases
07
Hospital mortality OR 2.3 for CLABSI vs non-infected lines, adjusted
08
Neonatal CLABSI attributable mortality 11%, low birth weight higher 20%
09
Recurrent CLABSI mortality 28% vs 14% first episode
10
Gram-negative CLABSI mortality 32% vs 22% Gram-positive, INICC
11
CLABSI increases LOS by 10 days average, cost study
12
MDR organism CLABSI mortality 45%, surveillance data
13
Burn patients CLABSI mortality 40%, matched controls 25%
14
90-day readmission 22% post-CLABSI discharge
15
Septic shock from CLABSI 50% mortality, ICU registry
16
Neonatal CLABSI neurodevelopmental impairment risk up 15%, long-term follow-up
17
CLABSI delays mechanical ventilation weaning by 4 days
18
In hematology, CLABSI mortality 20%, remission status affects
19
Post-CLABSI chronic kidney injury 12% incidence
20
1-year survival post-CLABSI 62% in elderly, cohort study
21
CLABSI attributable LOS 4.6 days in pediatrics
22
Fungal CLABSI mortality 42%, rare but high-risk
23
CLABSI increases ventilator days by 6.4, multivariate
Interpretation
Outcomes Interpretation
When you crunch the numbers from a hundred studies, the cold arithmetic of a CLABSI—a seemingly small infection from a central line—reveals itself as a cascading wager where the house always wins, taking a brutal toll in lives, years, and futures across every hospital unit from the NICU to the oncology ward.
More related reading
04 · Category
Prevention25 stats
01
Chlorhexidine bath reduces CLABSI by 45% (RR 0.55, 95% CI 0.42-0.72), meta-analysis 12 RCTs
02
Central line bundles reduce CLABSI by 66% in ICUs, pre-post studies average
03
Alcohol-impregnated port protectors lower CLABSI 53% (OR 0.47), cluster RCT 4,000 lines
04
Ultrasound-guided insertion reduces mechanical complications and infection risk by 30%, meta-analysis 14 RCTs
05
Daily CHG baths in ICU: CLABSI RR 0.59 (95% CI 0.45-0.77), Cochrane review
06
Antibiotic-coated catheters reduce CLABSI 41% (RR 0.59), 50 RCTs meta-analysis
07
Maximal sterile barrier precautions (MSBP) OR 0.52 vs standard, landmark trial
08
Chlorhexidine-silver sulfadiazine catheters RR 0.68 for CLABSI, meta-analysis
09
Line care bundle compliance >95% eliminates CLABSI in 80% ICUs, Michigan Keystone
10
Needleless connectors with split-septum reduce CLABSI 69%, before-after study
11
Education programs for staff reduce CLABSI 52% sustained, multi-center
12
Antimicrobial lock solutions RR 0.36 in HD catheters, meta-analysis 20 RCTs
13
Prompt line removal policy reduces CLABSI 40%, audit feedback study
14
Silver-impregnated dressings RR 0.54 for CRBSI, RCT 1,800 patients
15
Hand hygiene compliance >90% associated with 38% CLABSI drop, WHO campaign
16
Standardized insertion kits reduce infection 62%, cluster trial
17
CHG-impregnated sponges RR 0.56, large RCT 1,631 lines
18
Multidisciplinary rounds for line necessity halve CLABSI, quality improvement
19
Minocycline-rifampin catheters superior, RR 0.20 vs uncoated, trial
20
Transparent dressings with CHG RR 0.68, meta-analysis
21
Simulation training reduces insertion errors 50%, CLABSI down 44%
22
Ethanol lock therapy RR 0.25 in pediatrics, systematic review
23
Checklist use OR 0.48 for bundle compliance, WHO SAFE surgery
24
PDCA cycles reduce CLABSI 71% in neonatal ICU
25
Taurolidine locks RR 0.38, HD patients meta-analysis
Interpretation
Prevention Interpretation
The data scream that CLABSI is a multifaceted beast best slain by a coordinated arsenal of evidence—from sterile insertion theater and daily chlorhexidine bathing to antimicrobial locks and the humble checklist—because layering these strategies doesn't just add protection, it multiplies it.
05 · Category
Risk Factors23 stats
01
Femoral vein catheterization increases CLABSI risk by 2.5-fold compared to subclavian, CDC guidelines meta-analysis
02
Duration of catheterization >7 days raises CLABSI odds ratio (OR) 3.2 (95% CI 2.1-4.8), systematic review 2020
03
Mechanical ventilation associated with 1.8 OR for CLABSI in ICUs, multivariate analysis NHSN data
04
Total parenteral nutrition (TPN) use OR 2.4 for CLABSI (95% CI 1.9-3.0), meta-analysis 25 studies
05
Neutropenia (<500 neutrophils/mm³) increases CLABSI risk HR 4.1 in cancer patients, cohort study
06
Emergency catheter insertion OR 2.7 for CLABSI vs elective, prospective study 5,000 lines
07
Multilumen catheters (≥3 lumens) OR 1.9 vs single lumen, CDC review
08
Previous CLABSI history OR 3.5 for recurrence within 90 days, retrospective cohort
09
Obesity (BMI>30) associated with OR 1.6 for CLABSI, matched case-control
10
Dialysis patients CLABSI risk 2.2 times higher, USRDS data 2021
11
Gram-negative bacteria predominance in CLABSI risk with OR 2.1 in tropics, INICC
12
Nurse-to-patient ratio <1:2 OR 2.8 for CLABSI, staffing study 50 ICUs
13
Hypoalbuminemia (<3g/dL) OR 2.3 for CLABSI, prospective ICU study
14
Antimicrobial exposure prior OR 1.7, resistance development link
15
PICC lines in non-ICU OR 1.4 vs CVC, large cohort 100k lines
16
Trauma patients OR 2.6 for CLABSI, NSQIP data
17
Diabetes mellitus OR 1.5 (95% CI 1.2-1.9), meta-analysis 15 studies
18
Internal jugular site OR 2.0 vs subclavian, randomized trial
19
Age >65 years OR 1.4 for CLABSI, NHSN multivariate
20
Male gender OR 1.3 (95% CI 1.1-1.5), cohort 10k patients
21
Immunosuppression OR 3.0, transplant recipients study
22
Prolonged ICU stay >14 days OR 2.9 prior to line
23
Uremia OR 2.1 in non-dialysis CKD, case-control
Interpretation
Risk Factors Interpretation
Put simply, the data scream that our sickest patients with the most lines, ports, and interventions are sitting ducks for a CLABSI, proving infection is often a tax on the care we must give.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Clabsi Statistics. Gitnux. https://gitnux.org/clabsi-statistics
MLA
Stefan Wendt. "Clabsi Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/clabsi-statistics.
Chicago
Stefan Wendt. 2026. "Clabsi Statistics." Gitnux. https://gitnux.org/clabsi-statistics.
Sources & references
17 datasets cited across this report · attribution is report-level